<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466622</url>
  </required_header>
  <id_info>
    <org_study_id>2004-000792-33</org_study_id>
    <nct_id>NCT00466622</nct_id>
  </id_info>
  <brief_title>Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin</brief_title>
  <acronym>FlowMet</acronym>
  <official_title>Uterine Artery Blood Flow in Pregnant Women With Polycystic Ovary Syndrome(PCOS)Treated With Metformin - a Substudy to The PregMet Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FlowMet study is a &quot;sub-study&quot; of the PregMet study (registered in 2005).

      The aim of the FlowMet study is to register the possible effect of metformin on the blood
      flow of the uterine artery in pregnant PCOS women. The participants will be examined with
      ultrasound Doppler in gestational week 10-13:

        1. before and 3h after the first tablet intake of metformin/placebo

        2. and 10-14 days after inclusion in the trial

        3. blood flow in the umbilical artery and fetal cerebral artery in gestational week 24.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulsatility index of the uterine artery</measure>
    <time_frame>up to delivery</time_frame>
    <description>3 hrs before and after drug intake, 2 weeks after inclusion, and during medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood flow in the umbilical artery and fetal cerebral artery</measure>
    <time_frame>24 weeks gestational</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1000mg x 2 daily. Orally. From Weifa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 tablets x 2 daily. Orally From Weifa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>metformin 500mg tablets from Weifa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 tablets x 2 daily. Orally from Weifa</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Placebo tablets from Weifa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Same as in the PregMet study. As this study is a sub-study/extended study of the
             PregMet study, ONLY those included in the PregMet study (NCT00159536) can participate.

        Exclusion Criteria:

          -  Same as in the PregMet study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eszter Vanky, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Obstetrics and Gynecology, National Center for fetal Medicine, University Hospital of Trondheim</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Stridsklev S, Carlsen SM, Salvesen Ã˜, Clemens I, Vanky E. Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. J Clin Endocrinol Metab. 2014 Mar;99(3):972-7. doi: 10.1210/jc.2013-3227. Epub 2014 Jan 1.</citation>
    <PMID>24423336</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>pregnancy</keyword>
  <keyword>metformin</keyword>
  <keyword>blood flow</keyword>
  <keyword>Pulsatility index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

